CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention.

Leukemia · 2025 · PMC12055602 · PMID 40057636

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

Quantitative analysis of the percentage of CD45+ tumor cells expressing CD38 in each condition revealed a highly significant decrease in the cells treated with αCD38 antibody ( p < 0.0001 by an unpaired t test) (Fig. 2D ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.